KURA News and Press, Kura Oncology Inc. From 12/10/20

SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Hematology Summit. Troy ...

Kura Oncology (KURA) +2.9% pre-market after it announced the pricing of the underwritten public offering of 8.11M shares of its common stock at a price to the public of $37/share.The gross proceeds, before deducting underwriting discounts and commissions and other offering expe...

SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 8,110,000 shar...

The following slide deck was published by Kura Oncology, Inc. in conjunction with this event. For further details see: Kura Oncology (KURA) Presents At ASH Virtual Investor Event

Kura Oncology (KURA) commences an underwritten public offering, to issue and sell $200M of shares of its common stock.Underwriters' option to purchase up to an additional $30M of the shares of common stock offered in the public offering. For further details see: Kura commences public of...

Credit Suisse says it long-term thesis on Kura Oncology ([[KURA]] -0.9%) remains firmly intact as the ASH oral presentation reinforces the firm's confidence in the KO-539 development program. "The data to date supports KURA’s plans to move into Stage 1 of the Ph2 expansion cohorts (n=1...

Kura Oncology, Inc. (NASDAQ:KURA) is up ~16% in pre-market trading after announcing encouraging preliminary clinical data for KO-539 in a Phase 1/2A clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML).The data presented during the 62nd Am...

– Evidence of biologic activity observed in each dose-escalation cohort treated to date – – Clinical activity includes one CR in a patient with a NPM1 mutation and one CR in a patient with a SETD2/RUNX1 mutation – – Continuous daily dosing well t...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Satu...

The oncology market covers every area of cancer care, from diagnosis to treatment, and is one of the biggest sectors in the life science space. Cancer is the second leading cause of death worldwide, after cardiovascular diseases. Biotechnology and pharmaceutical companie...